General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies.
General education about policies to improve outcomes for patients with APOL-1 kidney disease.
Duration: February 20, 2015
to
May 31, 2023
General Issues: Health Issues , Medical/Disease Research/Clinical Labs , Medicare/Medicaid , Budget/Appropriations , Taxation/Internal Revenue Code , Defense , Trade (Domestic & Foreign)
Spending: about $1,000,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2015: U.S. Senate, House of Representatives, White House Office, Health & Human Services - Dept of (HHS), Homeland Security - Dept of (DHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Cheryl Jaeger Sr Policy Advisor, Majority Leader, Rep Eric Cantor
Shared Employee Ofc of Speaker & Ofc VA 7
Sr. LA to Rep Christopher Cox
Sr. Policy Advisor, Majority Whip Rep Blunt
Sr. Policy Advisor, Republican Whip Rep Cantor
Prof Staff House Committee on E&C
Shared employee, Ofc of the Speaker & ofc VA 7; Sr Policy Adv, Majority Leader, Rep E Cantor; Sr Policy Adv, Republican Whip, Rep E Cantor; Sr Policy Adv, Majority Whip, Rep R Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox
Shd employee, Ofc of the Speaker 7 Ofc of VA 7; Sr. Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Maj Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr LA to Rep C. Cox
Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep Cantor; Sr. Policy Adv, Republican Whip, Rep Cantor; Sr Policy Adv, Majority Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Cox
Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C;
Sr LA to Rep. Cox
Andrew Jones Legislative Counsel, Rep. Hinojosa; Legislative Director and Counsel, Rep. Lujan
Nicholas Karellas LA to Senator Christopher Bond; Tax Counsel, Rep Lynn Jenkins
Christopher Hatcher Sch C, Treasury; LD, Rep Scott McInnis
Sch. C, Treasury; Associate Staff, House Rules Committee; LD, Rep. Scott McInnis
Karina Lynch Staff, Senate Special Committee on Aging; Staff, Senate Committee on Government Affairs; Senate Committees on Aging and Gov. Affairs
Susan Hirschmann COS, Rep.Van Hilleary and Majority Whip
COS, Rep. Van Hilleary and Majority Whip Tom DeLay
Grant Barbosa Legislative Assistant, Sen. Harris; Legislative Assistant, Rep. Sander M. Levin; Congressional Hispanic Caucus Institute Fellow, Rep. Xavier Becerra
Mathew Hoekstra n/a
Matthew Hoekstra n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
2nd Quarter, 2023
Williams and Jensen, PLLC terminated an engagement in which they represented Vertex Pharmaceuticals Incorporated on July 14, 2023.
Original Filing: 301476147.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies to improve outcomes for patients with APOL-1 kidney disease.
Agencies Lobbied
U.S. Senate
1st Quarter, 2023
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 19, 2023.
Original Filing: 301457694.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Disease Research/Clinical Labs
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Implementation of P.L. 117-169 provisions related to Medicare prescription drugs. Education about non-opioid pain therapies.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about policies to improve outcomes for patients with APOL-1 kidney disease.
Agencies Lobbied
U.S. Senate
4th Quarter, 2022
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 20, 2023.
Original Filing: 301439480.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. General education about policies to improve health care outcomes for sickle cell disease. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to the regulation of pharmaceuticals, including S. 586, the NOPAIN Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues and general business tax issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
General education about policies to improve health care outcomes for sickle cell disease. Provisions included in the Consolidated Appropriations Act, FY 23 (P.L. 117-328) related to pharmaceuticals.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2022
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 19, 2022.
Original Filing: 301409828.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021 and H.R. 5376, "Inflation Reduction Act of 2022" (PL 117-169). Policies impacting U.S. address to the Covid-19 pandemic. General education about policies to improve health care outcomes for sickle cell disease.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities. H.R. 7667, the Food and Drug Amendments of 2022. S.4348, the FDA Safety and Landmark Act. H.R.6833 Making continuing appropriations for fiscal year 2023, and for other purposes (P.L.117-180), including FDA User Fee Reauthorization Act of 2022.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021 and H.R. 5376, "Inflation Reduction Act of 2022" (PL 117-169). Policies impacting U.S. address to the Covid-19 pandemic.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues and general business tax issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic. General education about policies to improve health care outcomes for sickle cell disease.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2022
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 20, 2022.
Original Filing: 301389784.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021. Policies impacting U.S. address to the Covid-19 pandemic. H.R. 5376, Build Back Better Act. General education about policies to improve health care outcomes for sickle cell disease.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities. H.R. 7667, the Food and Drug Amendments of 2022 and S.4348, the FDA Safety and Landmark Advancements Act (FDSLA).
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021. Policies impacting U.S. address to the Covid-19 pandemic. H.R. 5376, Build Back Better Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues and general business tax issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic. General education about policies to improve health care outcomes for sickle cell disease.
Agencies Lobbied
U.S. Senate
1st Quarter, 2022
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 19, 2022.
Original Filing: 301361736.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021. Policies impacting U.S. address to the Covid-19 pandemic. H.R. 5376, Build Back Better Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
General education about FDA approval policies and NIH research activities. Reauthorization of the Prescription Drug User Fee Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Orphan drug tax credit issues and general business tax issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic.
Agencies Lobbied
U.S. Senate
4th Quarter, 2021
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 20, 2022.
Original Filing: 301332442.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021. Policies impacting U.S. address to the Covid-19 pandemic. H.R. 5376, Build Back Better Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Orphan drug tax credit issues and general business tax issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2021
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 20, 2021.
Original Filing: 301308318.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. H.R. 3, Elijah E. Cummings Lower Drug Costs Now Act and H.R. 19, Lower Costs, More Cures Act of 2021. Policies impacting U.S. address to the Covid-19 pandemic. H.R. 5376, Build Back Better Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Health Issues/Medicaid
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
Orphan drug tax credit issues and general business tax issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2021
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 20, 2021.
Original Filing: 301285342.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues and general business tax issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2021
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 19, 2021.
Original Filing: 301256737.xml
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about federal policies impacting pharmaceutical development, approval, and reimbursement. Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including the American Rescue Plan Act of 2021, P.L. 117-2, H.R. 1319.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
4th Quarter, 2020
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 19, 2021.
Original Filing: 301234626.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
3rd Quarter, 2020
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 19, 2020.
Original Filing: 301214411.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136. Education regarding Executive Orders impacting drug pricing including Medicare rebate reform, the 340 B program, "buy America" proposals, and proposals to impose "most favored nation" pricing on Medicare Part B and D.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
2nd Quarter, 2020
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 17, 2020.
Original Filing: 301190415.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Issues related to pharmaceutical manufacturing and development.
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2020
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 17, 2020.
Original Filing: 301170489.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136.
Agencies Lobbied
U.S. Senate
4th Quarter, 2019
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 16, 2020.
Original Filing: 301106934.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidated Appropriations Act 2020.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019. H.R. 1865, Further Consolidated Appropriations Act 2020.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2019
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 17, 2019.
Original Filing: 301067407.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2019
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 17, 2019.
Original Filing: 301047061.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2019
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 22, 2019.
Original Filing: 301034325.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
General education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit issues.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2018
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 18, 2019.
Original Filing: 301008753.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act; H.R. 1892, the Bipartisan Budget Act of 2018
Agencies Lobbied
U.S. Senate
3rd Quarter, 2018
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 18, 2018.
Original Filing: 300988533.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act; H.R. 1892, the Bipartisan Budget Act of 2018
Agencies Lobbied
U.S. Senate
2nd Quarter, 2018
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 19, 2018.
Original Filing: 300969338.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act; H.R. 1892, the Bipartisan Budget Act of 2018
Agencies Lobbied
U.S. Senate
1st Quarter, 2018
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300958349.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Policies impacting Medicare Part D, H.R. 1625, Consolidated Appropriations Act; H.R. 1892, the Bipartisan Budget Act of 2018
Agencies Lobbied
U.S. Senate
4th Quarter, 2017
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 11, 2018.
Original Filing: 300922938.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Orphan drug tax credit. H.R. 1, Tax Cuts and Jobs Act.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2017
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 16, 2017.
Original Filing: 300904839.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2017
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 19, 2017.
Original Filing: 300888304.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2017
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 12, 2017.
Original Filing: 300864240.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 1628, American Health Care Act of 2017.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Prescription drug user fee agreements and general education about FDA approval policies and NIH research activities.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, reimbursement.
Agencies Lobbied
U.S. Senate
4th Quarter, 2016
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 17, 2017.
Original Filing: 300847592.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 34, 21st Century Cures Act, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
H.R. 34, 21st Century Cures Act; H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; H.R. 34, 21st Century Cures ACT. H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 17, 2016.
Original Filing: 300828446.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2016
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 13, 2016.
Original Filing: 300809177.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
1st Quarter, 2016
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on April 18, 2016.
Original Filing: 300792694.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. S. 2030 Advancing Targeted Therapies for Rare Diseases Act of 2015.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
4th Quarter, 2015
In Q4, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Jan. 14, 2016.
Original Filing: 300771684.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. H.R. 2029.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. H.R. 2029.
Agencies Lobbied
U.S. Senate
3rd Quarter, 2015
In Q3, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on Oct. 15, 2015.
Original Filing: 300753516.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. H.R. 209/S. 139 Ensuring Access to Clinical Trial Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
Williams and Jensen, PLLC amended a lobbying report for representation of Vertex Pharmaceuticals Incorporated in Q22015 on Aug. 10, 2015.
Original Filing: 300748778.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine. H.R. 209/S. 139 Ensuring Access to Clinical Trial Act.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
2nd Quarter, 2015
In Q2, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $30,000. The report was filed on July 15, 2015.
Original Filing: 300734921.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative, H.R. 6 (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
In Q1, Williams and Jensen, PLLC lobbied for Vertex Pharmaceuticals Incorporated , earning $20,000. The report was filed on April 13, 2015.
Original Filing: 300714574.xml
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Lobbying Issues
21st Century Cures Initiative (House Energy and Commerce Committee) and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
Type of Issue
Medical/Disease Research/Clinical Labs
Lobbying Issues
General education about policies impacting pharmaceutical development, approval, and reimbursement; 21st Century Cures Initiative (House Energy and Commerce Committee)and Innovation for Healthier Americans (Senate HELP Committee), including efforts to advance precision medicine.
Agencies Lobbied
U.S. Senate
1st Quarter, 2015
Williams and Jensen, PLLC filed a lobbying registration on Feb. 25, 2015 to represent Vertex Pharmaceuticals Incorporated, effective Feb. 20, 2015.
Original Filing: 300711190.xml
Issue(s) they said they’d lobby about: General education about federal policies impacting pharmaceutical development, approval, and reimbursement (including Medicare, Medicaid, Affordable Care Act issues). Developing policies for the Energy and Commerce 21st Century Cures and Senate HELP legislative initiatives, including efforts to advance precision medicine. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...